ERBB2 and cancer: Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) disease represents the largest group of cancer subtypes (68%), with the majority of patients in this group showing a lower proliferation index (luminal A 44%; luminal B 24%) (Voduc et al. 2010).